Placental Growth and Adverse Pregnancy Outcomes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1043 participants

Study Classification

OBSERVATIONAL

Study Start Date

2009-11-30

Study Completion Date

2016-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study to determine if measurement of maternal serum biomarkers and evaluation of the placenta by ultrasound can improve prediction of adverse pregnancy outcomes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Urine and Serum Concentrations of Pregnancy-Associated Compounds During Gestation

NCT03552055

Gestational Age

COMPLETED

Endothelial Progenitor Cells in Umbilical Cord Blood in Preeclampsia and IUGR

NCT00634855

Preeclampsia IUGR

TERMINATED

First Trimester Prediction of Preeclampsia and Fetal Growth Restriction

NCT02379494

Preeclampsia Fetal Growth Restriction

COMPLETED

Prenatal Sonographic Prediction of Placental Histology and Function

NCT06022458

Pregnancy Complications

RECRUITING

Screening for Intrapartum Fetal Compromise Using Placental Biomarkers

NCT07258329

Pregnant Women

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The placenta is known to play a vital role in maintaining a healthy pregnancy. Placental dysfunction is believed to be a driving factor in a variety of adverse obstetric outcomes, including fetal growth restriction and preeclampsia. Advances in 3D ultrasound have allowed for measurement of placental volumes during pregnancy. It may be that quantitative assessment of early placental growth can help identify pregnancies at risk for adverse outcome. Furthermore, various novel serum analytes have been proposed as predictors of adverse outcome. The investigators seek to prospectively measure placental volume and diameter at 11-14 weeks and 18-24 weeks to determine if placental growth can predict adverse outcome. In addition, the investigators seek to investigate the relationship between placental growth and serum levels of various biomarkers to see if improved detection of adverse outcome can be achieved.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Induced by Pregnancy Pre-Eclampsia IUGR

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

No treatment

Singleton pregnancies presenting to the Genetic Counselor for Sequential Screening prior to 14 weeks gestation.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* All singleton gestations presenting for Sequential Screen testing at HUP
* patients competent to provide verbal informed consent

Exclusion Criteria

* Multiple gestations
* patients not competent to provide informed consent
* patients found to be too late for the Sequential Screen
* pregnancy losses 20 weeks gestation
* major fetal anomalies
* patient delivering outside of the UPHS

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes